Method of Treating a Malignancy in a Subject and a Pharmaceutical Composition for Use in Same

Abstract

There is a disclosed a method of killing abnormal cells such as malignant cells including melanoma cells, using a virus recognising at least one of a cell adhesion molecule and a complement regulatory protein. The virus may be a member of the Picornaviridae family. Coxsackie A-group viruses have been found to be particularly suitable. The cell adhesion molecule is desirably a member of the immunoglobulin (Ig) superfamily. Typically, the complement regulatory protein will be DAF.

1 - 129 . (canceled) 
     
     
         130 . A method of treating non-small cell lung cancer (NSCLC) in a mammal, comprising administering to the mammal an effective amount of a human Enterovirus-C (HEV-C), wherein the virus is Coxsackievirus A21 (CVA21), that binds to intercellular adhesion molecule-1 (ICAM-1) for infectivity of the NSCLC cells and is thereby capable infecting the cells whereby death of the cells is caused, wherein CVA21 is administered intravenously, intratumorally, intraperitoneally or intramuscularly. 
     
     
         131 . The method of claim  1 , wherein the CVA21 binds to both ICAM-1 and decay accelerating factor (DAF) for infectivity of the abnormal cells. 
     
     
         132 . The method of claim  1 , wherein expression of ICAM-1 is upregulated on the NSCLC cells relative to normal said cells expressing their normal phenotype. 
     
     
         133 . The method of claim wherein expression of ICAM-1 is upregulated on the abnormal cells relative to cells of surrounding tissue in which the abnormal cells are found. 
     
     
         134 . The method of claim  1 , wherein the HEV-C is administered by injection. 
     
     
         135 . A method according to claim  1  wherein the virus is administered to the patient in a dosage greater than about 1×10 2  plaque forming units per ml of innoculant. 
     
     
         136 . A method according to claim  6  wherein the virus is administered to the patient in a dosage of between about 1×10 2  to 1×10 10  plaque forming units per ml of the innoculant.